A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Brief description of study

If you have been diagnosed with advanced or metastatic solid tumors, you may qualify to participate in this study.  The main goal of this phase 1/2 clinical trial is to evaluate the dafety, tolerability, and toxicities of the investigational drug, INCAGN01949 (an OX40 agonist monoclonal antibody).  In addition, we would like to study blood samples to understand how much INCAGN01949 is in the blood over time, which is known as pharmacokinetic (PK) testing.


Clinical Study Identifier: s16-00980
ClinicalTrials.gov Identifier: NCT02923349
Principal Investigator: Daniel Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.